产品介绍
Product Description
Application
AT7519 may be used to study its effects on cell viability and proliferation, cell cycle, apoptosis and pyroptosis in human glioblastoma cells.
Biochem/physiol Actions
AT7519 is a potent and selective cyclin dependent kinase (CDK) inhibitor (CDK5-p35/CDK2-CycA/CDK4-CycD1/CDK1-CycB IC50 = 18/44/67/190 nM; IC50 >10 μM against Aurora A, IR, MEK1, PDK1, c-abl) with antiproliferative activity in cancer cultures (IC50 = 82 nM/HCT116, 350 nM/A2780) and antitumor efficacy in mice in vivo (86% inhibition of A2780 xenograft tumor growth post 8-day treatment at 7.5 mg/kg b.i.d. i.p., 87% inhibition of HCT116 xenograft tumor growth post 10-day treatment at 9.1 mg/kg b.i.d. i.p.).
技术参数
Specifications
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | -10 to -25°C |
